A novel tumour marker related to the c-myc oncogene product.
We have studied the utility of the c-myc oncogene product as tumour marker using a set of monoclonal antibodies raised against synthetic peptides constructed from sequence data of the human c-myc oncoprotein. One antibody, Myc1-9E10, raised against the C-terminal 32 amino acids, has been shown to detect specifically the 62 kDa c-myc gene product in tumour cells. Immunoblotting of sera and urine with this antibody consistently revealed a single 40 kDa band (p40). Quantitative analysis using dilution dot immunoblotting demonstrated a considerable increase in the titre of p40 in the sera of 51 patients with a wide range of advanced solid tumours when compared with 17 healthy controls and 50 patients with non-malignant diseases. Serial measurement of the p40 titre in 12 patients with resected colorectal carcinoma shows a gradual return to normal with a half-life of 7 days. Our data suggests that p40 may be a useful new marker for monitoring tumour activity.
Chan
S
S
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Gabra
H
H
Hill
F
F
Evan
G
G
Sikora
K
K
D014408:Biomarkers, Tumor / Q000097:blood*; D003110:Colonic Neoplasms / Q000097:blood / Q000601:surgery; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011247:Pregnancy; D011518:Proto-Oncogene Proteins / Q000097:blood*; D016271:Proto-Oncogene Proteins c-myc; D012004:Rectal Neoplasms / Q000097:blood / Q000601:surgery
D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc